Celltrion Expands Global Market Share for Remsima
The biosimilar treatment has secured significant market portions across multiple countries in Asia and Latin America.
Updated on Oct. 20, 2026 in Healthcare
Live Poll
Do you believe the increased use of pharmaceutical biosimilars helps improve healthcare affordability for patients?
As of July 2026, Celltrion has achieved a 48 percent market share in Japan for its autoimmune treatment Remsima. The product continues to see high adoption rates across several international markets including Singapore, Brazil, and Costa Rica.
Why it matters
Celltrion's consistent growth highlights the increasing global acceptance of biosimilar alternatives to established treatments like Remicade. The company is actively leveraging public sector contracts to capture market share in developing regions.
Remsima currently holds 70 to 90 percent market share in Singapore, Hong Kong, Thailand, and Malaysia, alongside a 60 percent private market share in Brazil. Celltrion maintains 43 global subsidiaries, including 13 operations across Asia and Latin America.
The players
Celltrion
Celltrion is a South Korean biopharmaceutical company that specializes in the development and manufacturing of biosimilar drugs.
Johnson and Johnson
Johnson and Johnson is a multinational corporation that manufactures the reference drug Remicade.
The details
Remsima, a biosimilar of Johnson and Johnson's Remicade, has reached near 100 percent market dominance in Costa Rica when paired with Ruxience. Celltrion employs 80 staff members in Japan and continues to refine its penetration strategy by participating in public institutional bidding processes.
Timeline
July 2026: Remsima achieved a 48 percent market share in Japan.
Market Landscape
The global surge of Remsima reflects the broader industry shift toward biosimilars intended to disrupt the monopoly held by legacy biologic drugs. Celltrion's aggressive international expansion positions it as a major competitor against established pharmaceutical firms in emerging markets.
The widespread availability of biosimilars like Remsima can lead to lower healthcare costs for patients requiring autoimmune treatment. Consumers may experience better access to medication as health systems shift their procurement toward more affordable alternatives.
The takeaway
The success of Celltrion demonstrates how biosimilar manufacturers can successfully challenge high-cost specialty drugs in diverse international markets. Healthcare providers and patients should monitor regional drug availability as these lower-cost options continue to displace traditional brands.
Further reading
Learn more about sector trends in Healthcare.
Live Poll
Do you believe the increased use of pharmaceutical biosimilars helps improve healthcare affordability for patients?
